Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Parabolin is a long-acting injectable anabolic-androgenic steroid (AAS) containing trenbolone hexahydrobenzylcarbonate, a synthetic derivative of nandrolone. Developed to provide a slow release of the active hormone trenbolone into the bloodstream, it is characterized by its potent anabolic effects and significant androgenic activity. Trenbolone works by binding to and activating the androgen receptor, which enhances protein synthesis, nitrogen retention in muscles, and the production of insulin-like growth factor-1 (IGF-1). Unlike many other testosterone derivatives, trenbolone does not undergo aromatization to estrogen, making it highly valued in clinical and performance contexts for promoting lean muscle mass and strength without significant water retention. While historically used for treating conditions such as muscle wasting, malnutrition, and osteoporosis, its use is now primarily associated with specialized pharmaceutical markets and veterinary applications.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on trenbolone hexahydrobenzylcarbonate.